| Nov 19 |
Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model
|
| Nov 14 |
Scorpius Holdings GAAP EPS of -$1.43, revenue of $0.9M
|
| Nov 14 |
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
|
| Nov 4 |
Scorpius Holdings Announces Collaboration with Celltheon Corporation, a U.S.-Based Cell Line Development Company; First Client Signed Under New Partnership Agreement
|
| Oct 31 |
Scorpius Holdings Announces Implementation of New Cost Savings Measures Expected to Save Over $2 Million Annually
|
| Oct 2 |
Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats
|
| Sep 30 |
Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
|
| Sep 12 |
Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act
|
| Aug 20 |
Scorpius Holdings GAAP EPS of -$26.98, revenue of $0.8M
|
| Aug 20 |
Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
|
